NYSE Arca · TOVX
Theriva Biologics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TOVX: Nov 11, 2026
Theriva Biologics, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-0.45.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel- RTTNews · Aug 11, 1:21 PM EDTTheriva Biologics Advances VCN-01 Program; VIRAGE2 Trial Underway In Pancreatic Cancer(RTTNews) – Theriva Biologics, Inc. (TOVX), a clinical-stage company developing cancer therapeutics, recently reported its second-quarter 2026 financial results and provided operational updates, with investors focusing on the advancement of VCN-01 in metastatic pancreatic cancer
- RTTNews · Aug 7, 2:06 AM EDTTheriva Doses First Patient With VCN-01 In Phase 2a Trial For Pancreatic Cancer(RTTNews) – Theriva Biologics, Inc. (TOVX), a clinical-stage biotech company focused on developing therapeutics to treat cancer and rare diseases, announced the dosing of its first patient with VCN-01 in the Phase 2a VIRAGE2 trial.
- RTTNews · Jul 8, 4:40 AM EDTTheriva Biologics Advances VIRAGE2 Trial To Refine VCN-01 Dosing In Pancreatic Cancer(RTTNews) – Theriva Biologics Inc. (TOVX), a clinical-stage company developing therapies for cancer and related diseases, announced that the Spanish Agency of Medicines and Medical Devices (AEMPS) has authorized the initiation of its VIRAGE2 Phase 2a clinical trial.
- RTTNews · Jul 7, 10:19 AM EDTTheriva Gets AEMPS Approval For VIRAGE2 Phase 2a Trial Of VCN-01 In Metastatic PDAC; But Stock Down(RTTNews) – Theriva Biologics (TOVX), a clinical-stage company developing therapeutics designed to treat cancer, announced that the Spanish Agency of Medicines and Medical Devices (AEMPS) has authorised the company to initiate the Phase 2a VIRAGE2 clinical trial, evaluating VCN-0
- RTTNews · May 6, 5:32 AM EDTTheriva Q1 Net Loss Narrows; Plans Dosing Feasibility Study Of VCN-01 In H2,2026;Stock Down(RTTNews) – Theriva Biologics, Inc. (TOVX), a clinical-stage company, reported financial results for the first quarter ended March 31, 2026, reflecting a narrower net loss and highlighted near-term milestones for its lead candidate VCN-01.
- RTTNews · Apr 20, 12:41 AM EDTTheriva Biologics To Present VIRAGE Data; Stock Jumps(RTTNews) – Theriva Biologics (TOVX) is scheduled to present additional subgroup analyses from the VIRAGE study today at the American Association for Cancer Research (AACR) Annual Meeting 2026, which evaluates VCN-01 in combination with gemcitabine and nab-paclitaxel in newly dia
- Fintel · Apr 9, 9:28 AM EDTTheriva Biologics (TOVX) Price Target Decreased by 37.50% to 2.55The average one-year price target for Theriva Biologics (NYSEAM:TOVX) has been revised to $2.55 / share. This is a decrease of 37.50% from the prior estimate of $4.08 dated March 25, 2026. The price target is an average of many targets provided by analysts. Th
- Fintel · Apr 1, 6:47 AM EDTMaxim Group Upgrades Theriva Biologics (TOVX)Fintel reports that on March 31, 2026, Maxim Group upgraded their outlook for Theriva Biologics (NYSEAM:TOVX) from Hold to Buy. Analyst Price Forecast Suggests 1,983.76% Upside
- Fintel · Mar 27, 8:47 PM EDTTheriva Biologics (TOVX) Price Target Decreased by 42.86% to 4.08The average one-year price target for Theriva Biologics (NYSEAM:TOVX) has been revised to $4.08 / share. This is a decrease of 42.86% from the prior estimate of $7.14 dated February 21, 2026. The price target is an average of many targets provided by analysts.
- RTTNews · Mar 23, 10:08 AM EDTTheriva Biologics Shares Jump 50% After FDA Supports Phase 3 Plan For VCN-01(RTTNews) – Theriva Biologics (TOVX) saw its stock surge more than 50% after the company announced that the U.S. FDA provided positive End-of-Phase 2 feedback supporting the design of a Phase 3 trial for its lead candidate, VCN-01, in metastatic pancreatic ductal adenocarcinoma.
- RTTNews · Feb 20, 9:27 AM ESTWeekly Buzz: NRXP Sets The Path For NRX-100's NDA; IRON Gets FDA's CRL; TOVX Licenses SYN-020(RTTNews) – The biotech space this week witnessed significant key milestones, including FDA approvals, NDA path-setting meetings, rejections, licensing agreements, and oncology drug acquisitions.
- RTTNews · Feb 19, 7:35 AM ESTTheriva Licenses SYN-020 To Rasayana For Multiple Indications(RTTNews) – Theriva Biologics, Inc. (TOVX) has entered into an exclusive worldwide license agreement with Rasayana Therapeutics for the development and commercialization of SYN-020, an oral recombinant intestinal alkaline phosphatase enzyme.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Theriva Biologics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.